🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

10 recruiting trials

for Stargardt Disease Type 1 (STGD1)

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene NCT06435000n/a20 sites📍 San Diego📍 Aurora📍 Gainesville Splice Bio Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH) NCT06445322n/a9 sites📍 San Francisco📍 Gainesville📍 Baltimore Ascidian Therapeutics, Inc · Tests: Prescreening Assessments A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) NCT06942572Phase 1, Phase 25 sites📍 Aurora📍 Miami📍 Boston Splice Bio · Tests: SB-007 Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease) NCT07002398Phase 1, Phase 21 site📍 Shanghai VeonGen Therapeutics GmbH · Tests: VG801 A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants NCT07836452Phase 11 site📍 Melbourne City Therapeutics · Tests: CITY-RBP4, Placebo Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR) NCT06467344Phase 1, Phase 211 sites📍 San Francisco📍 Gainesville📍 Miami Ascidian Therapeutics, Inc · Tests: ACDN-01 Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease NCT07439887Phase 1, Phase 23 sites📍 Bakersfield📍 Pittsburgh📍 Bellaire Ray Therapeutics, Inc. · Tests: RTx-021 Study of ALK-001 on the Progression of Stargardt Disease NCT07419334Phase 314 sites📍 Phoenix📍 Aurora📍 Gainesville Alkeus Pharmaceuticals, Inc. · Tests: ALK-001, Placebo An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease NCT07063251EARLY Phase 11 site📍 Shanghai HuidaGene Therapeutics Co., Ltd. · Tests: HG005 Phase 1 Study of C.001 in Retinal Degeneration NCT07594236Phase 13 sites📍 Beverly Hills📍 Palo Alto📍 Sacramento Cellio Therapeutics Inc · Tests: Injection
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy